ArticleThe Laryngoscope2026
Corticosteroid Exposure in Chronic Rhinosinusitis and Global Airway Disease: Adrenal and Bone Impact.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate cumulative corticosteroid (CC) burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), with or without coexisting asthma (global airway disease, GAD), referred for biologic treatment, and to assess the prevalence of CC-related comorbidities, including secondary adrenal insufficiency, osteopenia and/or osteoporosis.
methodsProspective cohort study of adults with chronic rhinosinusitis with nasal polyps and/or GAD referred to tertiary care for biologic treatment evaluation: Assessments included DXA scan, corticosteroid case history, Synacthen test, and analyses of cumulative CS exposure (systemic [SCS], inhaled [ICS], and nasal [NCS]) using prescription data.
resultsOf 90 referred patients, 87 (97%) had complete data set and were included in the final cohort. The prevalence of Type 2 diabetes was significantly higher among patients with CRSwNP only compared with GAD (26% vs. 4%, p = 0.019), whereas subclinical adrenal suppression was detected only in the GAD group (6%, 4/70). Rates of osteopenia or osteoporosis were comparable (47% vs. 43%). Higher CC exposure was associated with lower bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip (all p < 0.02). Notably, these rates are considerably higher than those reported for the general Danish population aged ≥ 50 years, in which approximately 21.1% of women and 6.5% of men are estimated to have osteoporosis.
conclusionPatients with CRSwNP and GAD had a substantial CC burden from combined systemic, inhaled, and nasal steroid use. This was associated with subclinical adrenal suppression and reduced BMD, while Type 2 diabetes was more prevalent in patients only with CRSwNP. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.